Abstract
We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [-81.1 mU/ml mean difference; 95% confidence intervals (95% CI): -30.3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Alanine Transaminase / metabolism
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active*
-
Aspartate Aminotransferases / metabolism
-
HIV Infections / complications*
-
HIV Infections / drug therapy
-
HIV Infections / virology
-
HIV-1 / drug effects
-
Hepatitis B / complications*
-
Hepatitis B / drug therapy*
-
Hepatitis B / virology
-
Hepatitis B virus / drug effects
-
Humans
-
Lamivudine / administration & dosage
-
Lamivudine / therapeutic use*
-
Liver / enzymology
-
Male
-
Prospective Studies
-
Reverse Transcriptase Inhibitors / administration & dosage
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Treatment Outcome
Substances
-
Anti-HIV Agents
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
Aspartate Aminotransferases
-
Alanine Transaminase